CBX-12

N/A

Report date: 2026/02/17 20:00:13

Base Information

Drug NameCBX-12
Drug Alias Namealphalex™-exatecanCBX-12
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCybrexa Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesCybrexa TherapeuticsNational Cancer InstituteExelixis Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A